Siren Care is a technology company.
Siren Care has raised $31.2M across 6 funding rounds.
Siren Care has raised $31.2M in total across 6 funding rounds.
Siren Care has raised $31.2M in total across 6 funding rounds.
Siren Care's investors include Alpha JWC Ventures, foobar.vc, Kristian Segerstrale, Miki Kuusi, Mikko Kodisoja, Ascend Vietnam Ventures, BILL, Cisco Investments, DCM, Founders' Co-op, G2VP, Matrix.
Siren Care is a health technology company that develops smart socks embedded with microsensors for continuous temperature monitoring to prevent diabetic foot ulcers (DFUs) in patients with diabetes and neuropathy.[1][3][4][6] It serves high-risk patients, podiatrists, and healthcare providers through an FDA-registered Class I medical device paired with remote patient monitoring by licensed nurses, addressing the problem of DFUs—which affect over 30% of diabetic patients lifetime, cost the U.S. health system over $43 billion annually, and lead to over 100,000 lower limb amputations yearly—by detecting early inflammation via temperature changes, clinically proven to reduce ulcer risk by up to 68-87.5% and amputations by 83%.[1][3][5][6] The company has shown strong growth momentum, raising $11.8 million in Series B funding in 2021 from investors like DCM, Khosla Ventures, and Founders Fund, followed by a $9.5 million round in early 2025 led by an $8 million investment from Mölnlycke Health Care to accelerate development and adoption.[1][3][5]
Siren Care was founded in 2015 by Ran Ma (CEO), Henk Jan Scholten (COO), and Jie Fu (CTO), who developed proprietary technology to embed microsensors into fabric for mass production of affordable, washable smart textiles.[1][4] The idea emerged from addressing unmet needs in remote patient monitoring, starting with a focus on diabetic foot care; their first product, the temperature-monitoring sock, targets early detection of inflammation leading to DFUs.[1][3] Early traction included FDA registration, clinical validation of temperature monitoring as the gold standard (supported by 20+ years of studies), and partnerships with experts like podiatric surgeons Dr. Alexander Reyzelman (UCSF) and Dr. David G. Armstrong (USC).[1][4][5] Pivotal moments feature the 2021 Series B funding for commercial expansion and the 2025 Mölnlycke investment, enabling scaled adoption amid rising diabetes prevalence (830 million global cases).[1][3]
Siren Care rides the wave of digital health and MedTech innovation, specifically remote patient monitoring (RPM) and smart textiles, amid surging diabetes rates (830 million global sufferers) and strained healthcare systems facing physician shortages.[3][6] Timing is ideal post-COVID, with RPM adoption accelerating for chronic care; market forces like aging populations, rising DFU costs ($43B+ U.S. annually), and insurer demand for cost-saving tech favor scalable solutions like Siren's.[1][3] It influences the ecosystem by pioneering fabric-embedded sensors, potentially expanding to other biofeedback wearables, and partnering with giants like Mölnlycke to integrate into wound care workflows, setting standards for preventive diabetes management.[1][3][7]
Siren Care is poised for rapid scaling through Mölnlycke's investment and insurance coverage, likely expanding sock distribution via certified providers and exploring sensor applications beyond feet (e.g., full-body monitoring).[3][5] Trends like AI-driven triage, global diabetes growth, and value-based care will propel it, potentially capturing a slice of the $100B+ wound care market while evolving influence through tech licensing and ecosystem partnerships. This positions Siren as a leader in smart textiles, transforming reactive diabetes care into proactive prevention and echoing its founding mission to embed health tech seamlessly in daily life.[1][3][6]
Siren Care has raised $31.2M across 6 funding rounds. Most recently, it raised $9.0M Series B in August 2021.